unfractionated heparin + low molecular weight heparin + warfarin-St George's, University of London-cervical artery dissection

This entry refers to the specific anticoagulation treatment arm evaluated in the **Cervical Artery Dissection in Stroke Study (CADISS)**, a clinical trial led by **St George's, University of London**. The regimen consists of an initial course of heparin—either **unfractionated heparin (UFH)** or **low molecular weight heparin (LMWH)**—followed by oral anticoagulation with **warfarin**, targeting an International Normalized Ratio (INR) of 2.0–3.0 for a minimum of three months. This sequential therapy was investigated for the acute treatment of patients with cervical artery dissection (carotid or vertebral) to prevent recurrent stroke. The trial results indicated that recurrent stroke rates were low and that there was no significant difference in efficacy or safety between this anticoagulation approach and antiplatelet therapy.

Other names

Heparin followed by warfarinAnticoagulant arm of CADISS trial